These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 22000494)

  • 1. Metformin effects revisited.
    Andújar-Plata P; Pi-Sunyer X; Laferrère B
    Diabetes Res Clin Pract; 2012 Jan; 95(1):1-9. PubMed ID: 22000494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of metformin in patients with type 2 diabetes mellitus and chronic hepatitis C.
    Harris K; Smith L
    Ann Pharmacother; 2013 Oct; 47(10):1348-52. PubMed ID: 24259699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metformin hydrochloride in the treatment of type 2 diabetes mellitus: a clinical review with a focus on dual therapy.
    Setter SM; Iltz JL; Thams J; Campbell RK
    Clin Ther; 2003 Dec; 25(12):2991-3026. PubMed ID: 14749143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Metformin - mechanisms of action and use for the treatment of type 2 diabetes mellitus].
    Grzybowska M; Bober J; Olszewska M
    Postepy Hig Med Dosw (Online); 2011 May; 65():277-85. PubMed ID: 21677353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metformin in cancer treatment and prevention.
    Morales DR; Morris AD
    Annu Rev Med; 2015; 66():17-29. PubMed ID: 25386929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of the effects of thiazolidinediones and metformin on metabolic control in patients with type 2 diabetes mellitus.
    Seufert J; Lübben G; Dietrich K; Bates PC
    Clin Ther; 2004 Jun; 26(6):805-18. PubMed ID: 15262452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Metformin and AMPK: an old drug and a new enzyme in the context of metabolic syndrome].
    Santomauro Júnior AC; Ugolini MR; Santomauro AT; Souto RP
    Arq Bras Endocrinol Metabol; 2008 Feb; 52(1):120-5. PubMed ID: 18345405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cardiovascular effects of metformin: further reasons to consider an old drug as a cornerstone in the therapy of type 2 diabetes mellitus.
    Anfossi G; Russo I; Bonomo K; Trovati M
    Curr Vasc Pharmacol; 2010 May; 8(3):327-37. PubMed ID: 19485923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metformin and Inflammation: Its Potential Beyond Glucose-lowering Effect.
    Saisho Y
    Endocr Metab Immune Disord Drug Targets; 2015; 15(3):196-205. PubMed ID: 25772174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metformin monotherapy for type 2 diabetes mellitus.
    Saenz A; Fernandez-Esteban I; Mataix A; Ausejo M; Roque M; Moher D
    Cochrane Database Syst Rev; 2005 Jul; (3):CD002966. PubMed ID: 16034881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repurposing metformin for the prevention of cancer and cancer recurrence.
    Heckman-Stoddard BM; DeCensi A; Sahasrabuddhe VV; Ford LG
    Diabetologia; 2017 Sep; 60(9):1639-1647. PubMed ID: 28776080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New insights into the anti-diabetic actions of metformin: from the liver to the gut.
    Wu T; Horowitz M; Rayner CK
    Expert Rev Gastroenterol Hepatol; 2017 Feb; 11(2):157-166. PubMed ID: 27983877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metformin: from mechanisms of action to therapies.
    Foretz M; Guigas B; Bertrand L; Pollak M; Viollet B
    Cell Metab; 2014 Dec; 20(6):953-66. PubMed ID: 25456737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metformin improves blood glucose by increasing incretins independent of changes in gluconeogenesis in youth with type 2 diabetes.
    Cravalho CKL; Meyers AG; Mabundo LS; Courville A; Yang S; Cai H; Dai Y; Walter M; Walter PJ; Sharma S; Chacko S; Cogen F; Magge SN; Haymond MW; Chung ST
    Diabetologia; 2020 Oct; 63(10):2194-2204. PubMed ID: 32728891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
    Boland CL; Degeeter M; Nuzum DS; Tzefos M
    Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metformin for prevention of type 2 diabetes.
    Hess AM; Sullivan DL
    Ann Pharmacother; 2004; 38(7-8):1283-5. PubMed ID: 15150378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The mechanisms of action of metformin.
    Rena G; Hardie DG; Pearson ER
    Diabetologia; 2017 Sep; 60(9):1577-1585. PubMed ID: 28776086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes.
    Freemark M; Bursey D
    Pediatrics; 2001 Apr; 107(4):E55. PubMed ID: 11335776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is It Time to Change the Type 2 Diabetes Treatment Paradigm? No! Metformin Should Remain the Foundation Therapy for Type 2 Diabetes.
    Inzucchi SE
    Diabetes Care; 2017 Aug; 40(8):1128-1132. PubMed ID: 28733378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.